Radioiodine-associated exacerbation of graves' orbitopathy in the Japanese population: Randomized prospective study

Journal of Clinical Endocrinology and Metabolism

Volumn 100, Issue 7, 2015, Pages 2700-2708

  Watanabe, Natsuko ^a   Noh, Jaeduk Yoshimura ^a   Kozaki, Ai ^b   Iwaku, Kenji ^a   Sekiya, Kenichi ^a   Kosuga, Yuka ^a   Matsumoto, Masako ^a   Suzuki, Miho ^a   Yoshihara, Ai ^a   Ohye, Hidemi ^a   Kobayashi, Sakiko ^a   Kunii, Yo ^a   Mukasa, Koji ^a   Sugino, Kiminori ^a   Inoue, Tosyu ^b   Ito, Koichi ^a  

^a ITO HOSPITAL   (Japan)

^b Olympia Eye Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; IODINE; LEVOTHYROXINE; PREDNISOLONE; PROPYLTHIOURACIL; RADIOACTIVE IODINE; THIAMAZOLE; THYROID STIMULATING IMMUNOGLOBULIN;

ADULT; AGE; ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE DURATION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG DOSE REDUCTION; ENDOCRINE OPHTHALMOPATHY; FAMILY HISTORY; FEMALE; HUMAN; JAPAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SINGLE BLIND PROCEDURE; SMOKING HABIT; THYROID FUNCTION TEST; TREATMENT DURATION; TREATMENT OUTCOME; AGED; CHEMOPROPHYLAXIS; DISEASE COURSE; GRAVES DISEASE; GRAVES OPHTHALMOPATHY; PATHOLOGY; RADIATION INJURIES; YOUNG ADULT;

ADULT; AGED; CHEMOPREVENTION; DISEASE PROGRESSION; FEMALE; GRAVES DISEASE; GRAVES OPHTHALMOPATHY; HUMANS; IODINE RADIOISOTOPES; JAPAN; MALE; MIDDLE AGED; PREDNISOLONE; RADIATION INJURIES; YOUNG ADULT;

EID: 84942673436     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2014-4542     Document Type: Article

References (40)

1. Brent GA. Clinical practice. Graves' disease. N Engl J Med. 2008; 358:2594-2605.
2. Tallstedt L, Lundell G, Tørring O, et al. Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. The Thyroid Study Group. N Engl J Med. 1992;326:1733-1738.
3. Bartalena L, Marcocci C, Bogazzi F, et al. Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. N Engl J Med. 1998;338:73-78.
4. Träisk F, Tallstedt L, Abraham-Nordling M, et al. Thyroid-associated ophthalmopathy after treatment for Graves' hyperthyroidism with antithyroid drugs or iodine-131. J Clin Endocrinol Metab 2009;94:3700-3707.
5. Acharya SH, Avenell A, Philip S, Burr J, Bevan JS, Abraham P. Radioiodine therapy (RAI) for Graves' disease (GD) and the effect on ophthalmopathy: a systematic review. Clin Endocrinol (Oxf). 2008;69:943-950.
6. Ponto KA, Zang S, Kahaly GJ. The tale of radioiodine and Graves' orbitopathy. Thyroid. 2010;20:785-793.
7. Kung AW, Yau CC, Cheng A. The incidence of ophthalmopathy after radioiodine therapy for Graves' disease: prognostic factors and the role of methimazole. J Clin Endocrinol Metab. 1994;79:542-546.
8. Eckstein AK, Plicht M, Lax H, et al. Thyrotropin receptor autoantibodies are independent risk factors for Graves' ophthalmopathy and help to predict severity and outcome of the disease. J Clin Endocrinol Metab. 2006;91:3464-3470.
9. Bartalena L, Marcocci C, Bogazzi F, Panicucci M, Lepri A, Pinchera A. Use of corticosteroids to prevent progression of Graves' ophthalmopathy after radioiodine therapy for hyperthyroidism. N Engl J Med. 1989;321:1349-1352.
10. Bartalena L, Baldeschi L, Dickinson A, et al. Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol. 2008;158:273-285.
11. Bahn RS, Burch HB, Cooper DS, et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Endocr Pract. 2011;17:456-520.
12. Shiber S, Stiebel-Kalish H, Shimon I, Grossman A, Robenshtok E. Glucocorticoid regimens for prevention of graves' ophthalmopathy progression following radioiodine treatment: systematic review and meta-analysis. Thyroid. 2014;24:1515-1523.
13. Vaidya B, Williams GR, Abraham P, Pearce SH. Radioiodine treatment for benign thyroid disorders: results of a nationwide survey of UK endocrinologists. Clin Endocrinol (Oxf). 2008;68:814-820.
14. Tanda ML, Lai A, Bartalena L. Relation between Graves' orbitopathy and radioiodine therapy for hyperthyroidism: facts and unsolved questions. Clin Endocrinol (Oxf). 2008;69:845-847.
15. Lai A, Sassi L, Compri E, et al. Lower dose prednisone prevents radioiodine-associated exacerbation of initially mild or absent Graves' orbitopathy: a retrospective cohort study. J Clin Endocrinol Metab. 2010;95:1333-1337.
16. Yoshihara A, Noh JY, Watanabe N, et al. Lower incidence of postpartum thyrotoxicosis in women with Graves disease treated by radioiodine therapy than by subtotal thyroidectomy or with antithyroid drugs. Clin Nucl Med. 2014;39:326-329.
17. Mourits MP, Prummel MF, Wiersinga WM, Koornneef L. Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy. Clin Endocrinol (Oxf). 1997;47:9-14.
18. Werner SC. Modification of the classification of the eye changes of Graves' disease. Am J Ophthalmol. 1977;83:725-727.
19. Hiromatsu Y, Kojima K, Ishisaka N, et al. Role of magnetic resonance imaging in thyroid-associated ophthalmopathy: its predictive value for therapeutic outcome of immunosuppressive therapy. Thyroid. 1992;2:299-305.
20. Yokoyama N, Nagataki S, Uetani M, Ashizawa K, Eguchi K. Role of magnetic resonance imaging in the assessment of disease activity in thyroid-associated ophthalmopathy. Thyroid. 2002;12:223-227.
21. Suzuki Y, Nawata H, Soen S, et al. Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research: 2014 update. J Bone Miner Metab. 2014;32:337-350.
22. van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int. 2002;13:777-787.
23. Franklyn JA, Maisonneuve P, Sheppard MC, Betteridge J, Boyle P. Mortality after the treatment of hyperthyroidism with radioactive iodine. N Engl J Med. 1998;338:712-718.
24. Vannucchi G, Campi I, Covelli D, et al. Graves' orbitopathy activation after radioactive iodine therapy with and without steroid prophylaxis. J Clin Endocrinol Metab. 2009;94:3381-3386.
25. Inoue Y, Tsuboi T, Kouzaki A, Maeda T, Inoue T. Ophthalmic surgery in dysthyroid ophthalmopathy. Thyroid. 2002;12:257-263.
26. Lytton SD, Kahaly GJ. Bioassays for TSH-receptor autoantibodies: an update. Autoimmun Rev. 2010;10:116-122.
27. Grebe SK, Kahaly GJ. Laboratory testing in hyperthyroidism. Am J Med. 2012;125:S2.
28. Kamijo K, Murayama H, Uzu T, Togashi K, Kahaly GJ. A novel bioreporter assay for thyrotropin receptor antibodies using a chimeric thyrotropin receptor (mc4) is more useful in differentiation of Graves' disease from painless thyroiditis than conventional thyrotropin-stimulating antibody assay using porcine thyroid cells. Thyroid. 2010;20:851-856.
29. Diana T, Brown RS, Bossowski A, et al. Clinical relevance of thyroid-stimulating autoantibodies in pediatric Graves' disease-a multicenter study. J Clin Endocrinol Metab. 2014;99:1648-1655.
30. Noh JY, Hamada N, Inoue Y, Abe Y, Ito K, Ito K. Thyroid-stimulating antibody is related to Graves' ophthalmopathy, but thyrotropin-binding inhibitor immunoglobulin is related to hyperthyroidism in patients with Graves' disease. Thyroid. 2000;10:809-813.
31. Lytton SD, Ponto KA, Kanitz M, Matheis N, Kohn LD, Kahaly GJ. A novel thyroid stimulating immunoglobulin bioassay is a functional indicator of activity and severity of Graves' orbitopathy. J Clin Endocrinol Metab. 2010;95:2123-2131.
32. Giuliani C, Cerrone D, Harii N, et al. A TSHr-LH/CGr chimera that measures functional TSAb in Graves' disease. J Clin Endocrinol Metab. 2012;97:E1106-E1115.
33. Diana T, Kanitz M, Lehmann M, Li Y, Olivo PD, Kahaly GJ. Standardization of a bioassay for thyrotropin receptor stimulating autoantibodies. Thyroid. 2015;25:169-175.
34. Caraballo RS, Giovino GA, Pechacek TF, Mowery PD. Factors associated with discrepancies between self-reports on cigarette smoking and measured serum cotinine levels among persons aged 17 years or older: Third National Health and Nutrition Examination Survey, 1988-1994. Am J Epidemiol. 2001;153:807-814.
35. StanMN,Durski JM, Brito JP, Bhagra S, Thapa P, Bahn RS. Cohort study on radioactive iodine-induced hypothyroidism: implications for Graves' ophthalmopathy and optimal timing for thyroid hormone assessment. Thyroid. 2013;23:620-625.
36. Nagy EV, Toth J, Kaldi I, et al. Graves' ophthalmopathy: eye muscle involvement in patients with diplopia. Eur J Endocrinol. 2000;142: 591-597.
37. Hosten N, Sander B, Cordes M, Schubert CJ, Schörner W, Felix R. Graves ophthalmopathy: MR imaging of the orbits. Radiology. 1989;172:759-762.
38. Kirsch EC, Kaim AH, De Oliveira MG, von Arx G. Correlation of signal intensity ratio on orbital MRI-TIRM and clinical activity score as a possible predictor of therapy response in Graves' orbitopathy-a pilot study at 1. 5 T. Neuroradiology. 2010;52:91-97.
39. Tachibana S, Murakami T, Noguchi H, et al. Orbital magnetic resonance imaging combined with clinical activity score can improve the sensitivity of detection of disease activity and prediction of response to immunosuppressive therapy for Graves' ophthalmopathy. Endocr J. 2010;57:853-861.
40. Just M, Kahaly G, Higer HP, et al. Graves ophthalmopathy: role of MR imaging in radiation therapy. Radiology. 1991;179:187-190.